Biocon unit plans 15% stake sale to Serum Institute for access to vaccines By Reuters

© Reuters. FILE PHOTO: A research scientist works inside a laboratory of India’s Serum Institute, the world’s largest maker of vaccines, which is working on vaccines against the coronavirus disease (COVID-19) in Pune, India, May 18, 2020. REUTERS/Euan Rocha/File Pho

By Shivani Singh

BENGALURU (Reuters) -Biocon Ltd said late on Thursday its biologics unit will sell a 15% stake to a Serum Institute of India (SII) subsidiary for access to 100 million doses of vaccines annually for 15 years, including COVID-19 shots.

SII, which makes AstraZeneca (NASDAQ:)’s COVID-19 shot, branded as Covishield in India, is the world’s largest vaccine maker.

The deal with Serum Institute Life Sciences values Biocon Biologics at about $4.9 billion and will solely focus on COVID-19 vaccines in the initial years, the companies said.

The 15% stake in the Biocon unit is valued at more than $730 million, Biocon’s Executive Chairperson Kiran Mazumdar-Shaw said.

The unit, which makes pharmaceutical ingredients, will gain a foothold in the vaccine manufacturing space following the deal.

As part of the deal, the Biocon unit and the SII subsidiary will make and distribute vaccines and antibody treatments.

Biocon Biologics will also invest in setting up a research division for vaccines, with SII Chief Executive Officer Adar Poonawalla getting a seat on the board of the Biocon unit.

SII also expects to ramp up its Covishield manufacturing capacity to 200 million doses per month, Poonawalla said at a media briefing on Friday.

While there is a current ban on COVID-19 vaccine exports in India, Poonawalla said SII was trying to strengthen its supply chain and source raw materials from within the country as well.

SII is also manufacturing and stockpiling Novavax (NASDAQ:) Inc’s COVID-19 vaccine, which is yet to be granted approval by the Indian health authorities.

In January, Abu Dhabi-based investment firm ADQ invested $75.47 million in Biocon Biologics for a 1.8% stake.

Biocon Ltd’s shares rose as much as 4.6% early on Friday but gave up gains to trade 0.67% lower amid losses in the broader market. ()

($1 = 73.5350 Indian rupees)

Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures) and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn`t bear any responsibility for any trading losses you might incur as a result of using this data.

Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.

Most Related Links :
Business News Governmental News Finance News

Need Your Help Today. Your $1 can change life.

[charitable_donation_form campaign_id=57167]

Source link

Back to top button